New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
09:15 EDTANR, IPCI, CGI, TFM, SHPG, MIC, TXMD, GRPN, WLT, NURO, ABBVOn The Fly: Pre-market Movers
HIGHER: Shire (SHPG), up 1% after AbbVie (ABBV) raises buyout offer for fourth time, to GBP 22.44 in cash and 0.8568 AbbVie shares per Shire share. AbbVie shares down about 1% in pre-market trading following the news... Groupon (GRPN), up 5.7% after upgraded at B. Riley... TherapeuticsMD (TXMD), up 21.8% after FBR Capital initiated the stock with an Outperform rating and $34 price target... NeuroMetrix (NURO), up 45% after wearable technology for treatment of chronic pain cleared by FDA... Celadon Group (CGI), up 7% after upgraded at Stifel... Macquarie Infrastructure (MIC), up 6.3% after acquiring remainder of IMTT for $1.025B in cash, stock. LOWER: Intellipharmaceutics (IPCI), down 10% after Q2 earnings lower than expected... The Fresh Market (TFM), down 6.6% after downgraded at Goldman... Walter Energy (WLT), down 4%, Alpha Natural (ANR), down 1%, after coal sector estimates lowered at Morgan Stanley.
News For SHPG;ABBV;GRPN;TFM;NURO;TXMD;CGI;WLT;MIC;IPCI;ANR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 20, 2015
08:10 EDTSHPGShire price target raised to $247 from $228 at Jefferies
Subscribe for More Information
January 16, 2015
16:36 EDTSHPGMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
10:10 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
Subscribe for More Information
07:04 EDTABBVEnanta says EU grants marketing authorizations for AbbVie's Viekirax
Subscribe for More Information
05:05 EDTABBVAbbVie granted marketing authorization by EC for VIEKIRAX + EXVIERA
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX + EXVIERA. The treatment has been approved with or without ribavirin for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
January 15, 2015
11:20 EDTABBVGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:29 EDTGRPNOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTANROn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTGRPNGroupon upgraded at Evercore ISI
Subscribe for More Information
06:15 EDTGRPNGroupon upgraded to Hold from Sell at Evercore ISI
Subscribe for More Information
05:55 EDTTFMSupermarkets upgraded to Neutral from Cautious at Goldman Sachs
Subscribe for More Information
05:31 EDTANRAlpha Natural initiated with an Underweight at Barclays
Subscribe for More Information
January 14, 2015
12:25 EDTABBVAbbVie says pipeline is 'most robust it's ever been'
12:09 EDTABBVAbbVie says 'strongly' committed to dividend, returning cash to shareholders
Subscribe for More Information
12:00 EDTABBVAbbVie says guidance to be further refined as HCV launch progresses
11:59 EDTABBVAbbVie repeats FY15 adjusted EPS view $4.25-$4.45, consensus $4.30
Subscribe for More Information
10:39 EDTGRPNOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTTFMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:07 EDTNURONeuroMetrix reports 'strong' interest in Quell wearable pain relief technology
Subscribe for More Information
06:54 EDTTFMThe Fresh Market upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded The Fresh Market to Overweight with a $44 price target citing a favorable risk/reward following the recent pullback in shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use